FibroGen, Inc (FGEN) Set to Announce Earnings on Monday
FibroGen, Inc (NASDAQ:FGEN) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 6th. Analysts expect FibroGen to post earnings of ($0.36) per share for the quarter.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The firm had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. On average, analysts expect FibroGen to post $-1.93 EPS for the current fiscal year and $-1.5 EPS for the next fiscal year.
FibroGen, Inc (NASDAQ:FGEN) opened at 55.90 on Monday. The stock’s 50 day moving average price is $53.84 and its 200-day moving average price is $38.36. The firm’s market capitalization is $3.98 billion. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/30/fibrogen-inc-fgen-set-to-announce-earnings-on-monday.html.
A number of research analysts have recently commented on the company. Mizuho assumed coverage on FibroGen in a research note on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price for the company. Stifel Nicolaus restated a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. William Blair restated an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Finally, Leerink Swann restated an “outperform” rating and issued a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $65.67.
In other FibroGen news, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $43.73, for a total transaction of $1,689,552.28. Following the completion of the transaction, the chief executive officer now owns 3,330,780 shares in the company, valued at $145,655,009.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $52.24, for a total value of $104,480.00. Following the transaction, the director now owns 26,000 shares of the company’s stock, valued at approximately $1,358,240. The disclosure for this sale can be found here. Insiders have sold 552,828 shares of company stock valued at $27,774,395 in the last quarter. 14.90% of the stock is owned by company insiders.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.